Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy can trigger anxiety through gut brain interactions, central GLP-1 receptor effects, blood sugar shifts and psychological adjustments, though most people experience only mild symptoms that improve over time. If anxiety is severe or persists you may need dose adjustments, alternative medications or professional therapies to manage symptoms effectively.
See below for the complete details and critical factors to consider before making any healthcare decisions.
Wegovy (semaglutide) has emerged as a leading treatment for obesity and type 2 diabetes, delivering impressive weight‐loss results. Yet a notable number of people starting Wegovy report new or worsening anxiety. If you're asking "why does Wegovy cause anxiety?" you're not alone. In this article, we'll explore:
Throughout, we'll stick to clear, common‐language explanations and point you toward reliable next steps—without sugar‐coating the facts.
Wegovy is a once‐weekly injectable medication whose active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps with weight loss and blood‐sugar control by:
Most people tolerate Wegovy's gastrointestinal side effects—nausea, vomiting and diarrhea—which tend to decrease over time. But changes in mood and anxiety are increasingly reported.
The short answer is: we don't entirely know. But emerging research and clinical observations suggest several plausible mechanisms:
Central GLP-1 Receptors
Gut-Brain Axis Disruption
Blood Sugar and Hunger Fluctuations
Hormonal and Neurochemical Shifts
Psychological Adjustment
While gastrointestinal complaints dominate Wegovy trials, a closer look at mood effects reveals:
It's important to remember: clinical trials often underreport subtle mood changes. If you feel increased anxiety, trust your experience and discuss it with your healthcare team.
Normal worry can feel more intense on Wegovy. But you may need closer attention or a medication change if you experience:
These symptoms can affect daily life, work or relationships. If they become severe, seek medical help promptly.
Deciding to switch from Wegovy is a personal choice best made with your doctor. Consider these factors:
Severity of Anxiety
Dose Adjustment
Alternative Medications
Holistic Approach
If you and your provider agree that Wegovy's anxiety risk outweighs the benefits for you, they'll guide you through a safe transition plan.
If you and your doctor decide to continue Wegovy, these strategies may help:
Before adjusting any treatment, always consult your healthcare team. If you notice concerning symptoms—such as panic attacks, depression or suicidal thoughts—reach out to your provider immediately.
If you're experiencing anxiety or other troubling symptoms while on Wegovy and want guidance on whether they warrant immediate medical attention, try Ubie's free Medically Approved LLM Symptom Checker Chat Bot. It can help you organize your concerns and decide your next steps, though it's never a replacement for professional medical advice.
Always speak to a doctor before making decisions that could affect your health. Your healthcare team can help you weigh the benefits of continued Wegovy treatment against any risks, and guide you toward the safest, most effective path for your goals.
(References)
* Chai-Lee H, Lee S, Kim K, Kim H, Song D, Kang M, Woo SY, Kim Y, Seo H, Lim JS. Semaglutide and psychiatric adverse events: A disproportionality analysis of a real-world database. Front Pharmacol. 2023 Feb 1;14:1107530. doi: 10.3389/fphar.2023.1107530. PMID: 36761596; PMCID: PMC9910086.
* Yin P, Jiang M, Gao Q, Ma Z, Yu S, Cao S, Liu F. Psychiatric adverse events of GLP-1 receptor agonists: a disproportionality analysis of a pharmacovigilance database. Expert Opin Drug Saf. 2022 Mar;21(3):417-427. doi: 10.1080/14740338.2022.2035987. Epub 2022 Feb 7. PMID: 35140884; PMCID: PMC8810787.
* Hassan S, Akil M, Alnouri A, Al-Thani M, Al-Ansari M, Awad M, Yassine N, Farhat R, Farhat F. Impact of GLP-1 Receptor Agonists on Mental Health: A Systematic Review. Nutrients. 2023 Dec 27;16(1):119. doi: 10.3390/nu16010119. PMID: 38165074; PMCID: PMC10780287.
* Zhang P, Zheng S, Yang Q, Li R, Liu T, Ye D. Psychiatric adverse events associated with glucagon-like peptide-1 receptor agonists: a disproportionality analysis of the FAERS database. Psychiatry Clin Psychopharmacol. 2023 Oct 12;33(5):372-380. doi: 10.51430/PCCP.2023.12563. PMID: 37731778; PMCID: PMC10505186.
* Malik S, Khaliq I, Sarwar S, Usman M, Raza Z. GLP-1 receptor agonists and psychiatric disorders: a narrative review. Ther Adv Psychopharmacol. 2023 Jan 26;13:20451253231151603. doi: 10.1177/20451253231151603. PMID: 36718446; PMCID: PMC9884577.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.